Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Public ClinicalTrials.gov record NCT06979323. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess the Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized by an Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in a Sub Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
Study identification
- NCT ID
- NCT06979323
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 18, 2024
- Primary completion
- Jan 4, 2028
- Completion
- Feb 10, 2028
- Last update posted
- Jul 1, 2026
2024 – 2028
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Brooksville | Florida | 34613 | Recruiting |
| GSK Investigational Site | Plantation | Florida | 33324 | Recruiting |
| GSK Investigational Site | Kansas City | Kansas | 66160 | Recruiting |
| GSK Investigational Site | St Louis | Missouri | 63110 | Recruiting |
| GSK Investigational Site | New Brunswick | New Jersey | 08901 | Recruiting |
| GSK Investigational Site | New York | New York | 10029 | Recruiting |
| GSK Investigational Site | DuBois | Pennsylvania | 15801 | Recruiting |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140-5103 | Recruiting |
| GSK Investigational Site | McKinney | Texas | 75069 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06979323, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2026 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06979323 live on ClinicalTrials.gov.